Taiwanese President Tsai Ing-wen is expected to stop over in the U.S. on Friday on her way back from visiting diplomatic allies in the Caribbean, a move that's sure to make...China Politicsread more
Regional stability, oil prices and potential for war will all depend on what Iran does with its nuclear program in the event of the deal's termination.World Politicsread more
Libra and bitcoin are different in a lot of ways, from the technology behind them to the way they're used.Technologyread more
Stocks in major Asia Pacific markets made strong gains on Friday, as comments from a U.S. Federal Reserve official led to rising expectations the central bank could ease...Asia Marketsread more
Boeing will take a nearly $5 billion charge in the second quarter to compensate 737 Max customers as the planes remain grounded.Airlinesread more
Earlier, Williams delivered a speech at the annual meeting of the Central Bank Research Association in which he said, "It's better to take preventative measures than to wait...The Fedread more
The base version of the sports car will punch out 495 horsepower, 40 more than the seventh-generation car and enough to launch it from 0 to 60 in "less than three seconds"...Autosread more
Animation fans and Kyoto residents gathered at the site of Japan's worst mass killing in 18 years on Friday, offering flowers and prayers for the 33 people who died in an...Asia Newsread more
Trump said the USS Boxer destroyed Iran's drone in the Strait of Hormuz on Thursday in a "defensive action."Politicsread more
Microsoft beat on top and bottom lines, and guidance was just ahead of expectations, but the company's Azure growth is slowing down.Technologyread more
"We've seen Netflix stumble before, especially maybe after a price hike, but not quite like this," Jim Cramer says.Mad Money with Jim Cramerread more
A return to growth in its key respiratory business helped shares of GlaxoSmithKline (GSK) jump Wednesday, despite the pharmaceutical company posting a 3 percent fall in full-year revenue.
Last year was a troubling one for the U.K. company, which was hit by both declining sales of its blockbuster asthma drug, Advair, and a record fine over allegations of corruption in its business in China.
The FTSE 100-listed company posted a fall in 2014 revenue to £23 billion ($35 billion) on Wednesday, but said that its respiratory business would return to growth in 2016.
GSK traded over 3 percent higher after its results were out, the biggest gainer in the FTSE 100.
"The most important thing for us to get right in the short run is our respiratory business," said CEO Andrew Witty in a presentation on Wednesday.
"If we look beyond the current portfolio, the further pipeline in respiratory re-emphasizes why we believe that we are able to be optimist about a leader in respiratory, far into the future."
Witty said that sales of Advair were likely to continue falling 2015, but trumpeted the recent approvals of GSK's new respiratory drugs, Incruse and Arnuity.
"It is our intention to build a portfolio of respiratory medicines, not to have one medicine replace Advair one-for-one," Witty said.
The company said it expected maintain its dividend per share for 2015 at 80 pence—the same as last year—and that it expected to return £4 billion of net proceeds to shareholders from its asset swap with Novartis.
The deal will see GSK sell its oncology treatments to its Swiss rival, taking over its vaccine business in exchange, and is expected to be completed in the first half of 2015.
GSK also said it would make a decision on floating its HIV drugs unit, ViiV Healthcare, in 2015—a prospect it mooted back in October.
Earlier on Wednesday, U.K. media reported that GSK had hired three banks to advice on the potential IPO of the fast-growing ViiV unit, citing sources familiar with the matter.
Back in September, GSK was forecast to pay a $490 million fine, to settle allegations that it it paid doctors in China to prescribe its medicines. This was a record for a foreign company in the country.
Better publicity came when the company trumpeted progress in vaccinations against both Ebola and malaria.
"In both cases, GSK has the lead candidate vaccines for these two frightening diseases, "Witty said on Wednesday.
"Later in this year we should get feedback from the European regulator on the malaria vaccines and I am pleased to say that just a couple of days ago the first patients were vaccinated with our Ebola candidate vaccine in Liberia."
U.S. rival Merck also posted results on Wednesday, with earnings better than forecast. The New Jersey-based drugmaker recorded fourth-quarter earnings, excluding items, of 87 cents per share on revenue of $10.48 billion, versus analyst expectations of 85 cents on $10.5 billion in sales.